Azilsartan in Patients With Diabetic Kidney Disease and Hypertension
Status:
Recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
Hypertension is the most common complication in patients with diabetes nephropathy.
Strengthening blood pressure and blood sugar control is the basic treatment for patients with
diabetes nephropathy. Angiotensin receptor blocker (ARB) and angiotensin-converting enzyme
inhibitor (ACEI) are the first line drugs recommended in domestic and international
guidelines for diabetes patients to control hypertension. As a new ARB drug, azilsartan has
been found to have better antihypertensive effect than other ARB drugs. However, due to the
limited sample size and study time, azilsartan has no significant advantage over other ARB
drugs in terms of renal protection effect, and has not been systematically studied in
diabetes nephropathy population. This study is intended to evaluate the effect of azilsartan
on proteinuria and blood pressure improvement in patients with diabetes nephropathy and
hypertension through clinical randomized controlled study, so as to accumulate evidence-based
evidence of azilsartan in the comprehensive management of heart and kidney protection in this
group of people, and promote the development of comprehensive treatment for patients with
metabolic disease and renal injury combined with hypertension. This study will compare the
advantages and disadvantages of azilsartan and classical ARB drug losartan potassium in terms
of proteinuria, blood pressure control and renal function protection in patients with
diabetes nephropathy and hypertension; We propose that the main indicator is the change of
urinary albumin/creatinine ratio relative to the baseline, and the secondary indicator is the
change of 24-hour urinary protein relative to the baseline; Change of blood pressure relative
to baseline; Renal function, electrolyte and blood glucose.
Phase:
N/A
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University